# A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

> **NCT00322049** · PHASE1,PHASE2 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 51 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** Tetravalent live attenuated dengue vaccine
- **BIOLOGICAL:** Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine

## Key facts

- **NCT ID:** NCT00322049
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2018-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322049, "A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00322049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*